Search Results

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer: final results of the EUCROSS trial by Michels, Sebastian (Author) , Massutí, B. (Author) , Vasyliv, I. (Author) , Stratmann, J. (Author) , Frank, J. (Author) , Adams, A. (Author) , Felip, E. (Author) , Grohé, C. (Author) , Rodriguez-Abreu, D. (Author) , Bischoff, Helge (Author) , Carcereny i Costa, E. (Author) , Corral, J. (Author) , Pereira, E. (Author) , Fassunke, J. (Author) , Fischer, R. N. (Author) , Insa, A. (Author) , Koleczko, S. (Author) , Nogova, L. (Author) , Reck, M. (Author) , Reutter, T. (Author) , Riedel, R. (Author) , Schaufler, D. (Author) , Scheffler, M. (Author) , Weisthoff, M. (Author) , Provencio, M. (Author) , Merkelbach-Bruse, S. (Author) , Hellmich, M. (Author) , Sebastian, M. (Author) , Büttner, R. (Author) , Persigehl, T. (Author) , Rosell, R. (Author) , Wolf, J. (Author) ,

• lizenzpflichtig
• lizenzpflichtig

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program by Frost, Nikolaj (Author) , Christopoulos, Petros (Author) , Kauffmann-Guerrero, Diego (Author) , Stratmann, Jan (Author) , Riedel, Richard (Author) , Schaefer, Monica (Author) , Alt, Jürgen (Author) , Gütz, Sylvia (Author) , Christoph, Daniel C. (Author) , Laack, Eckart (Author) , Faehling, Martin (Author) , Fischer, Richard (Author) , Fenchel, Klaus (Author) , Haen, Sebastian P. (Author) , Heukamp, Lukas (Author) , Schulz, Christian (Author) , Griesinger, Frank (Author) ,

• lizenzpflichtig

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study$dreal world data of 123 NSCLC patients by Peled, Nir (Author) , Christopoulos, Petros (Author) ,

• lizenzpflichtig
• lizenzpflichtig

Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial by Michels, Sebastian (Author) , Bischoff, Helge (Author) ,

• Volltext